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Sj¨ ogren’s syndrome (SS) is a systemic autoimmune disease characterized by chronic inﬂammation of salivary and lachrymal
glands, and frequently accompanied by systemic symptoms. A subgroup of SS patients develops malignant B cell non-Hodgkin’s
lymphoma (NHL), usually of the mucosa-associated lymphoid tis s u e( M A L T )t y p ea n dv e r yo f t e nl o c a t e di nt h em a j o rs a l i v a r y
glands. Currently, there is a lack of evidence-based intervention therapy which may inﬂuence SS-related chronic inﬂammation
and lymphoproliferation. B cells are involved in the pathogenesis of SS, and B cell downregulation may lead to a decrease of
disease activity. Rituximab (RTX), a chimeric monoclonal antibody targeting the CD20 antigen on the B cell surface, has been
successfully investigated in other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, ANCA-
associated vasculitis, and mixed cryoglobulinemic syndrome. Preliminary experiences of RTX therapy in SS patients with or
without a lymphoproliferative disorder suggest that SS patients with more residual exocrine gland function might better beneﬁt
from RTX. Eﬃcacy of RTX in SS-associated B-cell lymphoma, mainly in low-grade salivary gland lymphomas, remains an open
issue.
Copyright © 2009 Luca Quartuccio et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Sj¨ ogren’s syndrome (SS) is a systemic autoimmune dis-
ease characterized by chronic inﬂammation of salivary
and lachrymal glands, frequently accompanied by systemic
symptoms [1]. The presence of various autoantibodies such
as the rheumatoid factor (RF) and anti-SSA/SSB antibodies,
as well as hypergammaglobulinemia, reﬂects B cell hyper-
activity [1]. SS has the strongest link with non-Hodgkin’s
lymphoma (NHL) compared with other autoimmune dis-
eases, and similar to mixed cryoglobulinemic syndrome,
which may be associated with SS [2–4]. About ﬁve percent
of patients with SS develop a malignant B cell NHL,
usually of the mucosa-associated lymphoid tissue (MALT)
type and frequently located in the parotid glands [1, 5].
Currently, there is a lack of evidence-based intervention
therapy which may inﬂuence SS-related chronic inﬂamma-
tion and lymphoproliferation. In particular, the optimal
treatment for NHL complicating SS is not clearly deﬁned.
The majority of SS patients with indolent NHL may require
only surveillance and no therapy; however, a subgroup of SS
patients may suﬀer from aggressive lymphomas, that is, de
novo diﬀuse large cell B-cell lymphomas, or indolent or low-
gradelymphomasprogressedintoaggressivelymphomas[2].
Although SS has been regarded as T-cell-mediated disease,
B cells comprise in general up to 20% of the mononuclear
cells in the salivary glands [1, 6]. B-cell activating factor
(BAFF) promotes B-cell survival and diﬀerentiation, and SS
patients frequently have elevated serum levels of BAFF [7].
BAFF overproduction in mouse models results in several
autoimmune phenomena, resembling SS and lupus features,
as well as in B-cell hyperplasia and lymphoma development
[8, 9]. Thus, B cells are involved in the pathogenesis of SS,
and B cell downregulation may be a target of treatment.2 International Journal of Rheumatology
Rituximab (RTX), a chimeric monoclonal antibody direct
against the CD20 molecule expressed on the surface of
mature B cells, is then a putative therapy for both sicca
syndrome and SS-related B-cell lymphoproliferation [10].
Patients with more residual exocrine gland function, for
example, those with SS of shorter duration, might better
beneﬁt from systemic therapy, as well as SS patients with
thecryoglobulinemicsyndrome,asreportedinrecentstudies
[11, 12]. However, in earliest experience reported between
the years 2000 and 2002 by our group, RTX eﬃcacy on
nonmalignant lymphoproliferation in SS was inconstant,
and a scarce eﬀect on sicca symptoms was observed [13].
Then, a careful use of RTX in selected cases seemed more
rationale, in the lack of additional clear-cut evidence of some
beneﬁts. By contrast, RTX monotherapy or RTX combined
with cytotoxic agents in chemotherapeutic regimens may
have a stronger rationale in SS patients with CD20-positive
B-cell NHL [3, 11, 14–22].
2.Pathologic andMolecularBackground,
and Involvement of BAFF
Low-grade marginal zone MALT-type lymphoma, usually
involving the parotid glands, is an important complication
of primary SS [1, 2, 23–25]. A 250-fold increase in risk of
parotid gland NHL and a dramatic 1000-fold increase in risk
of parotid gland MALT lymphoma were recently observed
[2]. However, a positive associations between SS and other
subtypes, most notably diﬀuse large B-cell lymphoma and
nodal lymphomas, was reported [2]. Parotid lymphoma may
evolve from parotid lymphoepithelial sialadenitis (LESA),
which may in turn present with diﬀerent pathologic and
molecular patterns of B cell proliferation, that is, fully
benignorwithlymphoproliferativelesionbyhistopathology;
and poly-, oligo-, or monoclonal-ﬂuctuating, -persistent or
-disseminated by molecular studies [23]. A notable histo-
logical feature in SS is LESA characterized by a lymphoid
population surrounding and inﬁltrating salivary ducts, with
disorganizationandproliferationoftheductalepithelialcells
(lymphoepithelial lesions) [26]. These lesions ﬁrst appear as
small clusters and later enlarge to organize lymphoid follicle-
like structures with germinal centers. The phenotype of the
immunocompetent cells present in lymphoepithelial lesions,
mainly composed of primed CD4+ T lymphocytes, suggests
functional structures in which activated B cells produce
autoantibodies [27–29]. Therefore, LESA is a condition in
which MALT is found in the salivary glands, a site not
normally containing lymphoid tissue. The MALT acquired
due to the autoimmune process may represent the substrate
f r o mw h i c ht h eBc e l ll y m p h o m ad e v e l o p si nS S[ 1, 23, 30].
The characterization of the earlier events of lympho-
proliferation in SS is still ill-deﬁned. Because a mono-
clonal expansion does not necessarily constitute a malignant
lymphoma, monoclonal B cell populations in early LESA
represent nonmalignant expansions rather than an early
NHL, at least in most cases [23]. The presence of the same
B-cell clone in metachronous biopsies of the same aﬀected
tissue from the same patient indicates a higher risk of NHL
evolution, while diﬀerent clones in metachronous biopsies
are consistent with a nonmalignant B-cell expansion [23,
31]. Thus, the diﬀerent types of B cell clonal expansion
(oligoclonal or monoclonal, smaller or larger, ﬂuctuating or
established, localized or disseminated) in SS salivary MALT
imply a diﬀerent risk of lymphoma progression in our
experience. Since the transition of LESA into a malignant
lymphoma is generally considered to represent a multistep
process, molecular studies of clonal B-cell expansion appear
of value to better deﬁne the risk of lymphoma evolution in
SS [23]. It has been speculated that lymphoproliferation is
driven by antigenic stimulation, and that during the course
ofthediseaseadditionaloncogeniceventsoccur,suchascon-
stitutive activation of signaling pathways after chromosomal
translocations or inactivation of tumor suppressor genes.
Cytokine and chemokine microenvironments in target
tissues may play a role in the lymphoproliferation in the
course of SS. Recently, Barone et al. demonstrated the
association between lymphoid chemokines CXCL13 and
CCL21 and areas of reactive lymphoid proliferation in the
salivary glands with LESA, while CXCL12 was observed
predominantly in inﬁltrated ducts and malignant B cells,
suggesting that in salivary gland MALT lymphoma, the
lymphoid chemokines CXCL13 and CCL21 are directly
implicated in the organization of ectopic lymphoid germinal
centers, whereas CXCL12 is associated with the inﬁltrated
epithelium and malignant B cell component and is possibly
involved in the regulation of malignant B cell survival
[32]. The diﬀerential expressions of CXCL13, CCL21, and
CXCL12 within SS salivary glands with LESA and MALT-
Lymphoma regulate diverse functional microenvironments
of lymphoid organization, respectively orchestrating the
reactive lymphoid areas that favor the perpetuation of
the autoreactive response and the malignant areas where
expansion and proliferation of the B cell clones take place
[32].
Overproduction of BAFF, implicated in the maturation
and survival of B lymphocytes, may play a role in the
mechanism of salvage of autoreactive B cell (e.g., RF-positive
B-cells) and in the B-cell hyperplasia, as demonstrated in
mouse models. Mice carrying a transgene for BAFF become
highly susceptible to the autoimmunity-lymphoproliferation
complex development [8, 9]. Analysis of BAFF plasma levels
in SS has shown that BAFF is higher in patients than in
controlsandstronglycorrelateswiththetiterofautoantibod-
i e ss u c ha sR Fa n da n t i - R o / S S A[ 7]. A strong expression of
BAFF was also detected in inﬁltrating lymphocytes, in ductal
and acinar epithelial cells in target tissue biopsies from SS
patients [20, 33–35]. The prolonged survival of autoreactive
B cells may promote production of autoantibodies or the
later development of NHL in SS patients. Finally, TNF−/−
BAFF transgenic mice also showed a high incidence of B cell
lymphomas [36].
RTX exposure increases BAFF overproduction [12,
20]. Recently, we described in detail one of reported SS
cases with lymphoma undergoing RTX therapy [20]. In
such a case, BAFF overproduction after RTX administra-
tion was decreased, but not halted by high-dose steroids
(prednisone 1mg/kg/day for one month). However, BAFFInternational Journal of Rheumatology 3
overproduction reappeared at even higher levels after steroid
dose reduction. Pre- and post-RTX parotid gland biopsies
demonstrated the persistence of BAFF and BAFF-receptor
overexpression at the histopathologic and molecular level
[20]. Lymphoma in this patient did not respond to RTX
therapy, and BAFF was considered as a key resistance factor
[20].
In a second case of SS with parotid LESA, who developed
rheumatoid arthritis after interferon-alpha therapy for SS,
RTX therapy was administered at time of relapse of polysyn-
ovitis in a long-term period of follow-up (107 months), with
4 complete cycles of RTX and 6 subsequent single doses of
RTX every 6–12 months. Repeated parotid biopsy after 4
full RTX cycles given in 3,5 years revealed a reduction in
the parotid lymphoid inﬁltrate and recovery of acinar and
lobular structures at histopathologic level. However, PAN-
B and PAN-T antibody stains disclosed a very large amount
of B and T cell inﬁltrates, similar to baseline analysis. Thus,
prolonged RTX therapy, that is, at least 4 full cycles, may
not aﬀect parotid lymphoproliferation in SS. Pers et al. [37]
demonstrated that baseline serum levels of BAFF correlated
inversely with the duration of B cell depletion after RTX
in SS. B cells were absent in salivary glands analysed 12
months after RTX therapy in sequential lip biopsies, but
they were again detected 24 months after RTX. Memory and
transitional type 1 (T1) B cells were the ﬁrst repopulating
B cells. Recovery of salivary gland B cells occurred with
four B cell subsets: plasmablasts, T1 B cells, mature Bm2
cells, and memory B cells. Increased numbers of Bm2 cells
and decreased memory B cells reappeared with time. B
cell repopulation in SS glands may be modulated by BAFF
and, notably, is followed by reconstitution of the preexisting
abnormalities [37].
By integrating the clinical and molecular results herein
presented, the concept that BAFF plays a crucial role in B-
cell proliferation in the course of SS, at least in a subset of
patients, is reinforced, and BAFF tissue overexpression may
therefore represent a mechanism of RTX resistance in B-cell
lymphoproliferation associated with SS.
3. Data from CaseReports and from
Open-LabelTrials
Since 2002 up to the time of searching (February 2009),
26 patients with SS and lymphoma treated with RTX
have been reported in 11 PubMed indexed articles by
combining the key words “Sj¨ ogren’s syndrome”, “rituximab”,
and “lymphoma” [3, 11, 14–22]. Sixteen (17/26) were in Ann
Arbor Stage I-II, while the remaining were in stage III (1/26)
or IV (8/26). Thirteen (14/26) were salivary gland MALT-
type lymphomas, mainly parotid gland MALT-type lym-
phomas (11/26). In 10/26 patients, RTX was administered
in combination with other cytotoxic agents (with cyclophos-
phamide/doxorubicin/vincristine/prednisone (CHOP) reg-
imen in 9 patients, with cyclophosphamide/vincristine/
prednisone (CVP) regimen in 1), while in the remaining
16 cases RTX was used in monotherapy (9/26), or with
methylprednisolone pulses, low to medium doses of steroids,
antimalarials, methotrexate, azathioprine (5/26), or after
local radiotherapy (1/26). Globally, response rate to RTX
(alone or added to chemotherapy) in SS-related B-cell NHL
was 20/26 (77%).
However,whileallthetenpatientstreatedwithcombined
therapy with RTX plus cytotoxic agents in chemotherapeutic
regimens had a good outcome, response was observed in
10/16 (62,5%) of the 16 cases treated with RTX without
cytotoxic therapy. Of the 10 NHLs responding to RTX
without chemotherapy, 8 were in I-II Ann Arbor stage
(treated with RTX monotherapy) and two were in IV Ann
Arbor stage (one also treated with local radiotherapy). Six
out of the 10 NHLs responding to RTX without chemother-
apy had salivary MALT-type lymphomas, and the other 4
disclosed nonsalivary MALT-type lymphomas. Interestingly,
allthenonrespondinglymphomas(6/6)involvedthesalivary
glands (Table 1). Thus, salivary gland NHLs, if compared to
MALT NHLs involving other organs, seemed more resistant
to RTX therapy in the lack of concomitant chemotherapy.
Finally, a higher incidence of human antichimeric anti-
bodies (HACA) and serum sickness reaction was reported
after RTX in SS., if compared to other autoimmune diseases
[12, 19].
4. PersonalExperience
Early data on SS patients treated with RTX were pre-
sented by our Group in 2002 [13], showing a lack of
eﬀect of RTX on nonmalignant parotid monoclonal B-cell
lymphoproliferation in LESA. Unexpectedly, lung NHL in
one of these two cases showed persistent regression after
RTX [12]. At present, we have treated 6 SS patients with
RTX in the attempt to improve SS-related manifestations.
Indications for RTX were the following: B-cell NHL in 4
patients and nonmalignant parotid lymphoproliferation in
2 patients (LESA; one of them also with cryoglobuline-
mic syndrome). Other clinical manifestations are described
in Table 2, including rheumatoid arthritis in one patient
with parotid LESA [38]. RTX was administered at the
standard haematological doses, that is, 375mg/m2 weekly
for 4 weeks. One patient underwent two subsequent full
cycles of RTX, and another patient underwent 4 full cycles
and then 6 single (600mg) RTX infusions at the time
of rheumatoid arthritis relapse. Sicca syndrome responded
much better in the patient’s perspective than in clini-
cal objective evaluation, with about half of the patients
reporting an improvement in oral and ocular dryness,
while objective tests (i.e., Schirmer test and unstimulated
sialometry) remained unchanged or worsened in all the
patients. However, constitutional symptoms such as fatigue,
low-grade fever, arthralgias, and myalgias, improved in all
patients. Parotid swelling decreased or disappeared in 5/6
patients. Cutaneous vasculitis responded in 2/3 patients;
sensory peripheral neuropathy improved in 2/3 patients;
polysynovitis improved in 3/4 patients. Cryoglobulins and
the RF (when present) decreased but did not become
negative at month + 6, and anti-SSA/SSB autoantibodies
remained positive in all the 6 cases. Lymphoma histotypes4 International Journal of Rheumatology
Table 1: Patients with SS and lymphoma treated with rituximab.









Shih, 2002 1 Parotid gland MALT-type/no IE Yes No
Somer, 2003 1 Parotid gland MALT-type/no IE Yes No
Voulgarelis, 2004∗ 4
(1) Salivary gland MALT-type/yes∗ IV Yes (1) CHOP
(2) Nodal marginal zone/no∗ IIE Yes (2) CHOP
(3) Pulmonary MALT-type/yes∗ IV Yes (3) CHOP
(4) Salivary gland MALT-type/yes∗ IV Yes (4) CHOP
Harner, 2004 1 Nodal marginal zone/Pulmonary
MALT-type/no IIE Yes No
Ramos-Casals, 2004 2 (1) Ovarian MALT-type/yes IV Yes (1) CHOP
(2) Ocular MALT-type/yes IV Yes (2) Local radiotherapy
Pijpe, 2005 1 Parotid gland MALT-type/no IE Yes No
Gottenberg, 2005# 2 (1) Digestive tract MALT-type/no# IE Yes (1) MP 500mg ×4, HQ
(2) Salivary gland MALT-type/no# IE No (2) No
Pijpe, 2005 7
(1) Parotid gland MALT-type/no IE No (1) No
(2) Parotid gland MALT-type/no IE No (2) PDN 15mg/day
(3) Parotid gland MALT-type/no IE Yes (3) No
(4) Parotid gland MALT-type/no IE Yes (4) No
(5) Parotid gland MALT-type/no IE No (5) PDN 7.5mg/day, MTX
(6) Parotid gland MALT-type/no IE Yes (6) PDN 5mg/day, AZA
(7) Parotid gland MALT-type/no IE No (7) No
Voulgarelis, 2006∗ 6
(1) Nodal marginal zone/no II Yes (1) CHOP
(2) DLBCL/no II Yes (2) CHOP
(3) Salivary gland MALT-type/yes∗ IV Yes (3) CHOP
(4) Nodal marginal zone/no∗ IIE Yes (4) CHOP
(5) Pulmonary MALT-type/yes∗ IV Yes (5) CHOP
(6) Salivary gland MALT-type/yes∗ IV Yes (6) CHOP
Seror, 2007# 5
(1) Salivary gland MALT-type/no# IE No (1) No
(2) Nodal marginal zone/yes IV Yes (2) No
(3) Gastric/pulmonary MALT-type/no IV Yes (3) Mini-CHOP
(4) Gastric MALT-type/no# IE Yes (4) HQ
(5) DLBCL/no III Yes (5) CHOP
Quartuccio, 2008◦ 1 Parotid gland MALT-type/no◦ IE No High-dose steroids
Carbone J, 2008 1 Low-grade marginal zone/yes IV Yes CVP
Present report◦ 4
Parotid gland MALT-type/no◦ IE No High-dose steroids
Lung MALT-type /no IE Yes No
DLBCL + salivary MALT-type/no IV Yes CNOP
Parotid gland MALT-type/yes IV Yes Parotidectomy
Legend: pts, patients; MALT, mucosa-associated lymphoid tissue; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; AZA, azathioprine; PDN,
prednisone; MTX, methotrexate; MP, methylprednisolone; DLBCL, diﬀuse large B-cell lymphoma; HQ, hydroxychloroquine.
∗There is some patients’ overlapping between the cases reported in Voulgarelis, 2004 and Voulgarelis, 2006.
#There is some patients’ overlapping between the cases reported in Gottenberg, 2005 and Seror, 2007.
◦There is some patients’ overlapping between the cases reported in Quartuccio, 2008 and present report.
and staging were one parotid MALT-type low-grade B-cell
NHL (stage IE) [20], one lung MALT-type low-grade B-
cell NHL associated with parotid LESA (stage IE) [10, 23],
one aggressive diﬀuse large B-cell NHL associated with
salivary MALT-type low-grade B-cell NHL (stage IV), and
one parotid gland low-grade MALT-type B-cell NHL with
bone marrow NHL inﬁltration (stage IV). RTX combination
therapy with cytotoxic agents was administered in one
patient (aggressive diﬀuse large B-cell lymphoma). One
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(parotid gland MALT-type monolateral lymphoma with
bone marrow inﬁltration). Complete response was observed
in3/4NHLpatients,withnorelapseinthelong-termfollow-
up (mean survival time 5.5 years). One patient died for right
heart failure at month + 39 (secondary to severe mitral and
tricuspidal valve insuﬃciency). Of note, in the patient with
lung MALT-type low-grade NHL associated with parotid
LESA, biopsy-demonstrated [10, 23], a complete response
to RTX monotherapy was observed in lung MALT-type
lymphoma, while nonmalignant proliferation (LESA) in the
parotid glands persisted [10] with parotid swelling still
e v i d e n ta tp r e s e n t .
Treatment with RTX was well tolerated. Serum sickness
reactions were not recorded.
Overall, RTX proved eﬀective on SS systemic symptoms,
ineﬀective on sicca syndrome, ineﬀective on LESA (docu-
mented by repeated biopsy) [10, 23], and of value, alone or
added to chemotherapy, in SS-related NHL.
5. Conclusion
Despite the eﬃcacy of RTX in constitutional and systemic
features associated with B cell expansion in SS (i.e. cryo-
globulinemic vasculitis) [12], the usefulness of RTX in B-
cell lymphoproliferation in SS is controversial. Aggressive
lymphomas require standard chemotherapeutic regimens,
which were recently integrated with RTX [15]. However,
the majority of SS patients with lymphoma show indo-
lent, nonaggressive lymphomas, mainly salivary (parotid)
MALT-type lymphomas in stage I-II, with a performance
status 0-1 [39]. An aggressive approach would be more
dangerous rather than curative in this subset. Parotid MALT-
type NHL associated with SS appears to be to be more
resistant to RTX as compared with the other types of
lymphoma in SS, and RTX may be as well ineﬀective
in SS-related LESA. RTX may fail to deplete B-cells in
the salivary tissue due to key pathogenetic factors in the
local microenvironment, as recently well described in a
murine model [40]. A still unknown local trigger is also
suspected. Local factors such as BAFF and chemokines
(CXCL13, CCL21, CXCL12) appear to be implicated, and
BAFF inhibition plus anti-CD20 therapy allowed reaching
much higher degrees of B-cell depletion in mouse models
[40].
Thus, by integrating clinical and molecular data, RTX
monotherapy may not represent an ideal treatment for SS-
associated lymphoproliferation, and B-cell recovery after
RTX,whenpresent,showedtherestorationofpreviousB-cell
abnormalities [37]. Combining RTX with cytotoxic agents
in aggressive lymphomas, or with the recently available anti-
BAFF agents in indolent lymphomas and prelimphomatous
conditions (e.g., persistent parotid swelling with ongoing
monoclonal B-cell expansion, and/or type II mixed cry-
globulinemia) could prove more eﬀective, and dedicated
studies are needed. Persistence of antigen-driven stimulation
of the immune system in the target tissue may ﬁnally
require an etiologic treatment, as in gastric low grade NHL
[41].
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